MDFA is Australia’s largest source of research funding in the field of macular disease outside of government
Composition and functionality of high-density lipoprotein in age-related macular degeneration and a high-risk disease phenotype
Redefining macular disease diagnosis to improve access to emerging therapies
Investigating mitochondrial dysfunction in macular degeneration – towards new treatments and biomarkers
Evaluating the potential of hyperspectral imaging for detecting and monitoring geographic atrophy Accurate monitoring of
Vabysmo is a new treatment for age-related macular degeneration and diabetic macular oedema and is now available on the Pharmaceutical Benefits Scheme (PBS) in Australia
MDFA 2022 research update
MDFA is committing to macular disease research
Faricimab has taken one step closer towards clinics in Australia.